Symbols / ABVC
ABVC Chart
About
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 34.02M |
| Enterprise Value | 37.65M | Income | -5.08M | Sales | 797.92K |
| Book/sh | 0.51 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 16 | IPO | — |
| P/E | — | Forward P/E | -3.18 | PEG | — |
| P/S | 42.64 | P/B | 2.72 | P/C | — |
| EV/EBITDA | -7.71 | EV/Sales | 47.18 | Quick Ratio | 0.04 |
| Current Ratio | 0.63 | Debt/Eq | 17.06 | LT Debt/Eq | — |
| EPS (ttm) | -0.28 | EPS next Y | -0.44 | EPS Growth | — |
| Revenue Growth | 104.50% | Earnings | 2023-05-15 16:00 | ROA | -17.22% |
| ROE | -47.71% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -146.52% | Profit Margin | 0.00% | Shs Outstand | 24.30M |
| Shs Float | 18.96M | Short Float | 1.17% | Short Ratio | 4.61 |
| Short Interest | — | 52W High | 5.48 | 52W Low | 0.61 |
| Beta | 0.23 | Avg Volume | 63.40K | Volume | 23.95K |
| Target Price | — | Recom | None | Prev Close | $1.40 |
| Price | $1.40 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.40
Latest analyst target
3. DCF / Fair value
$-1.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.40
Low
—
High
—
Mean
—
- ABVC BioPharma First Half 2025 Earnings: US$0.19 loss per share (vs US$0.36 loss in 1H 2024) - Yahoo Finance Fri, 15 Aug 2025 07
- ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView Mon, 03 Nov 2025 08
- ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance Mon, 03 Nov 2025 08
- How ABVC BioPharma Inc. stock performs during Fed tightening cycles - Portfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru hu, 05 Feb 2026 04
- symbol__ Stock Quote Price and Forecast - CNN Wed, 21 Feb 2024 00
- ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Yahoo Finance ue, 23 Sep 2025 07
- ABVC BioPharma faces Nasdaq delisting over share price - Investing.com Fri, 12 Jul 2024 07
- AiBtl signs $667m licensing deal for ABVC’s CNS drug - Pharmaceutical Technology Fri, 17 Nov 2023 08
- ABVC - Abvc Biopharma Inc Latest Stock News & Market Updates - Stock Titan hu, 05 Aug 2021 01
- RSI Check: Whats the analyst consensus on ABVC - 2025 Volatility Report & Fast Moving Trade Plans - baoquankhu1.vn Wed, 04 Feb 2026 12
- Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention - Bloomberg.com Mon, 01 Nov 2021 07
- ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology - Yahoo Finance hu, 26 Jun 2025 07
- ABVC BioPharma Names Uttam Yashwant Patil Chief Executive - marketscreener.com Mon, 26 Jun 2023 07
- ABVC Stock Price and Chart — NASDAQ:ABVC - TradingView Sat, 26 Jun 2021 06
- ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - Yahoo Finance hu, 15 Aug 2024 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -7.50K | -41.83K | -79.18K | 42.25K |
| TaxRateForCalcs | 0.02 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -3.98M | -6.13M | -14.82M | -11.13M |
| TotalUnusualItems | -364.31K | -199.20K | -377.03K | 156.47K |
| TotalUnusualItemsExcludingGoodwill | -364.31K | -199.20K | -377.03K | 156.47K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -4.90M | -7.79M | -16.42M | -12.84M |
| ReconciledDepreciation | 200.92K | 380.39K | 23.80K | 11.99K |
| ReconciledCostOfRevenue | 763.00 | 302.04K | 286.42K | 5.09K |
| EBITDA | -4.34M | -6.33M | -15.20M | -10.97M |
| EBIT | -4.54M | -6.71M | -15.22M | -10.98M |
| NetInterestIncome | -738.54K | -1.13M | -106.15K | -184.01K |
| InterestExpense | 825.90K | 1.31M | 293.97K | 227.21K |
| InterestIncome | 87.36K | 185.48K | 187.82K | 43.20K |
| NormalizedIncome | -4.55M | -7.63M | -16.13M | -12.95M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -4.90M | -7.79M | -16.42M | -12.84M |
| TotalExpenses | 5.21M | 6.92M | 16.08M | 11.70M |
| TotalOperatingIncomeAsReported | -4.71M | -6.77M | -15.11M | -11.71M |
| DilutedAverageShares | 11.67M | 4.34M | 3.17M | 2.51M |
| BasicAverageShares | 11.67M | 4.34M | 3.17M | 2.51M |
| DilutedEPS | -0.42 | -1.80 | -5.20 | -5.10 |
| BasicEPS | -0.42 | -1.80 | -5.20 | -5.10 |
| DilutedNIAvailtoComStockholders | -4.90M | -7.79M | -16.42M | -12.84M |
| NetIncomeCommonStockholders | -4.90M | -7.79M | -16.42M | -12.84M |
| NetIncome | -4.90M | -7.79M | -16.42M | -12.84M |
| MinorityInterests | 356.16K | 492.79K | -110.86K | -802.96K |
| NetIncomeIncludingNoncontrollingInterests | -5.26M | -8.28M | -16.31M | -12.04M |
| NetIncomeContinuousOperations | -5.26M | -8.28M | -16.31M | -12.04M |
| TaxProvision | -110.54K | 256.01K | 797.78K | 825.02K |
| PretaxIncome | -5.37M | -8.02M | -15.51M | -11.21M |
| OtherIncomeExpense | 74.21K | -129.91K | -294.03K | 318.26K |
| OtherNonOperatingIncomeExpenses | 438.51K | 69.28K | 83.00K | 161.78K |
| SpecialIncomeCharges | 0.00 | -110.12K | 0.00 | |
| WriteOff | 0.00 | 110.12K | 0.00 | |
| GainOnSaleOfSecurity | -364.31K | -199.20K | -266.91K | 156.47K |
| NetNonOperatingInterestIncomeExpense | -738.54K | -1.13M | -106.15K | -184.01K |
| InterestExpenseNonOperating | 825.90K | 1.31M | 293.97K | 227.21K |
| InterestIncomeNonOperating | 87.36K | 185.48K | 187.82K | 43.20K |
| OperatingIncome | -4.71M | -6.77M | -15.11M | -11.35M |
| OperatingExpense | 5.21M | 6.62M | 15.80M | 11.70M |
| OtherOperatingExpenses | -360.90K | |||
| ResearchAndDevelopment | 179.27K | 1.06M | 2.69M | 1.00M |
| SellingGeneralAndAdministration | 5.03M | 5.55M | 13.10M | 11.05M |
| GeneralAndAdministrativeExpense | 5.03M | 5.55M | 13.10M | 11.05M |
| OtherGandA | 2.26M | 5.37M | 6.07M | 5.75M |
| SalariesAndWages | 2.77M | 185.93K | 7.04M | 5.31M |
| GrossProfit | 508.83K | -149.61K | 683.37K | 350.71K |
| CostOfRevenue | 763.00 | 302.04K | 286.42K | 5.09K |
| TotalRevenue | 509.59K | 152.43K | 969.78K | 355.80K |
| OperatingRevenue | 509.59K | 152.43K | 969.78K | 355.80K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 730.64K | 26.55K | 27.53K | |
| OrdinarySharesNumber | 13.14M | 7.91M | 3.29M | 2.89M |
| ShareIssued | 13.87M | 7.94M | 3.31M | 2.89M |
| NetDebt | 1.54M | 1.73M | 1.81M | |
| TotalDebt | 2.43M | 2.60M | 3.05M | 3.11M |
| TangibleBookValue | 1.23M | 1.55M | 3.10M | 8.84M |
| InvestedCapital | 3.02M | 3.34M | 4.99M | 10.48M |
| WorkingCapital | -4.38M | -4.45M | -2.56M | 3.96M |
| NetTangibleAssets | 1.23M | 1.55M | 3.10M | 8.84M |
| CapitalLeaseObligations | 640.39K | 809.28K | 1.16M | 1.47M |
| CommonStockEquity | 1.23M | 1.55M | 3.10M | 8.84M |
| TotalCapitalization | 1.23M | 1.55M | 3.10M | 8.84M |
| TotalEquityGrossMinorityInterest | 723.96K | 1.25M | 3.24M | 8.87M |
| MinorityInterest | -502.18K | -300.64K | 137.55K | 26.69K |
| StockholdersEquity | 1.23M | 1.55M | 3.10M | 8.84M |
| OtherEquityInterest | 31.04K | -451.48K | -1.35M | -2.26M |
| GainsLossesNotAffectingRetainedEarnings | 445.67K | 516.39K | 517.13K | 539.66K |
| OtherEquityAdjustments | 445.67K | 516.39K | 517.13K | 539.66K |
| TreasuryStock | 8.91M | 8.90M | 9.10M | 9.10M |
| RetainedEarnings | -68.95M | -64.05M | -54.90M | -38.48M |
| AdditionalPaidInCapital | 78.60M | 73.98M | 67.94M | 58.11M |
| CapitalStock | 13.87K | 7.94K | 3.29K | 28.93K |
| CommonStock | 13.87K | 7.94K | 3.29K | 28.93K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.82M | 6.53M | 6.34M | 4.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 258.49K | 429.14K | 799.81K | 1.14M |
| OtherNonCurrentLiabilities | 21.68K | 21.68K | 7.98K | 10.58K |
| LongTermDebtAndCapitalLeaseObligation | 236.81K | 407.46K | 791.83K | 1.12M |
| LongTermCapitalLeaseObligation | 236.81K | 407.46K | 791.83K | 1.12M |
| CurrentLiabilities | 6.56M | 6.10M | 5.54M | 3.69M |
| OtherCurrentLiabilities | 302.27K | 427.35K | 468.15K | |
| CurrentDeferredLiabilities | 81.11K | 79.50K | 10.98K | 10.98K |
| CurrentDeferredRevenue | 81.11K | 79.50K | 10.98K | 10.98K |
| CurrentDebtAndCapitalLeaseObligation | 2.19M | 2.19M | 2.26M | 1.99M |
| CurrentCapitalLeaseObligation | 403.58K | 401.83K | 369.31K | 347.10K |
| CurrentDebt | 1.79M | 1.79M | 1.89M | 1.64M |
| OtherCurrentBorrowings | 950.05K | 886.52K | 186.88K | |
| LineOfCredit | 810.25K | 899.25K | 1.89M | 1.64M |
| CurrentNotesPayable | 30.00K | 0.00 | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.15M | 1.05M | 568.87K | |
| PayablesAndAccruedExpenses | 2.83M | 2.36M | 2.23M | 1.69M |
| CurrentAccruedExpenses | 2.06M | 2.07M | 1.87M | 1.30M |
| Payables | 773.04K | 286.44K | 359.99K | 393.42K |
| DuetoRelatedPartiesCurrent | 773.04K | 173.49K | 359.99K | 393.42K |
| TotalTaxPayable | 0.00 | 112.95K | 0.00 | |
| AccountsPayable | 0.00 | |||
| TotalAssets | 7.54M | 7.78M | 9.58M | 13.70M |
| TotalNonCurrentAssets | 5.36M | 6.13M | 6.59M | 6.04M |
| OtherNonCurrentAssets | 133.12K | 141.23K | ||
| NonCurrentPrepaidAssets | 1.82M | 1.97M | 3.03M | 1.31M |
| NonCurrentDeferredAssets | 0.00 | 117.11K | 981.91K | |
| NonCurrentDeferredTaxesAssets | 0.00 | 117.11K | 981.91K | |
| DuefromRelatedPartiesNonCurrent | 0.00 | 113.52K | 865.48K | 818.18K |
| NonCurrentAccountsReceivable | 113.52K | 865.48K | 818.18K | |
| InvestmentsAndAdvances | 2.26M | 2.53M | 842.07K | 932.75K |
| OtherInvestments | 847.25K | 842.07K | ||
| InvestmentinFinancialAssets | 790.25K | 847.25K | 842.07K | |
| AvailableForSaleSecurities | 790.25K | 847.25K | 842.07K | |
| LongTermEquityInvestment | 1.47M | 1.68M | 0.00 | |
| InvestmentsinAssociatesatCost | 1.47M | 1.68M | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| Goodwill | 0.00 | |||
| NetPPE | 1.15M | 1.38M | 1.74M | 2.00M |
| AccumulatedDepreciation | -3.34M | -3.34M | -3.30M | -3.31M |
| GrossPPE | 4.49M | 4.71M | 5.04M | 5.31M |
| ConstructionInProgress | 7.40M | 0.00 | ||
| OtherProperties | 640.39K | 809.28K | 1.16M | 1.47M |
| MachineryFurnitureEquipment | 1.29M | 1.31M | 1.29M | 1.21M |
| BuildingsAndImprovements | 2.22M | 2.23M | 2.23M | 2.24M |
| LandAndImprovements | 338.97K | 363.42K | 361.19K | 400.09K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.18M | 1.66M | 2.99M | 7.65M |
| OtherCurrentAssets | 96.21K | 101.05K | 150.24K | 528.35K |
| RestrictedCash | 615.43K | 656.62K | 1.31M | 736.67K |
| PrepaidAssets | 1.21M | |||
| Inventory | 0.00 | 25.98K | ||
| InventoriesAdjustmentsAllowances | 0.00 | -155.37K | ||
| FinishedGoods | 0.00 | 96.72K | ||
| WorkInProcess | 0.00 | 0.00 | ||
| RawMaterials | 0.00 | 84.62K | ||
| Receivables | 1.16M | 759.57K | 1.37M | 426.09K |
| DuefromRelatedPartiesCurrent | 1.16M | 758.04K | 1.27M | 145.40K |
| AccountsReceivable | 0.00 | 1.53K | 98.33K | 280.69K |
| AllowanceForDoubtfulAccountsReceivable | -616.41K | -616.50K | ||
| GrossAccountsReceivable | 616.41K | 618.03K | ||
| CashCashEquivalentsAndShortTermInvestments | 313.12K | 139.47K | 161.06K | 5.94M |
| OtherShortTermInvestments | 64.74K | 79.31K | 75.80K | 108.15K |
| CashAndCashEquivalents | 248.38K | 60.16K | 85.27K | 5.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.81M | -4.21M | -7.52M | -7.62M |
| RepurchaseOfCapitalStock | -7.32K | 0.00 | ||
| RepaymentOfDebt | -356.17K | -1.00M | 0.00 | -514.24K |
| IssuanceOfDebt | 372.10K | 1.46M | 350.00K | 240.76K |
| IssuanceOfCapitalStock | 31.04K | 1.05M | 3.66M | 11.12M |
| CapitalExpenditure | -21.20K | -119.69K | -17.50K | |
| InterestPaidSupplementalData | 22.54K | 33.18K | 285.46K | 333.87K |
| IncomeTaxPaidSupplementalData | 25.86K | 27.39K | 1.60K | 0.00 |
| EndCashPosition | 863.82K | 716.78K | 1.39M | 6.57M |
| BeginningCashPosition | 716.78K | 1.39M | 6.57M | 5.00M |
| EffectOfExchangeRateChanges | -24.59K | 2.12K | -67.34K | -28.02K |
| ChangesInCash | 171.62K | -677.07K | -5.11M | 1.59M |
| FinancingCashFlow | 1.98M | 3.87M | 4.01M | 10.00M |
| CashFlowFromContinuingFinancingActivities | 1.98M | 3.87M | 4.01M | 10.00M |
| NetOtherFinancingCharges | 599.55K | -49.00K | -850.43K | |
| ProceedsFromStockOptionExercised | 1.34M | 2.41M | 0.00 | |
| NetCommonStockIssuance | 23.72K | 1.05M | 3.66M | 11.12M |
| CommonStockPayments | -7.32K | 0.00 | ||
| CommonStockIssuance | 31.04K | 1.05M | 3.66M | 11.12M |
| NetIssuancePaymentsOfDebt | 15.93K | 462.62K | 350.00K | -273.47K |
| NetShortTermDebtIssuance | 312.94K | 462.62K | 350.00K | -95.73K |
| ShortTermDebtPayments | -29.15K | -1.00M | 0.00 | -100.00K |
| ShortTermDebtIssuance | 342.10K | 1.46M | 350.00K | 4.26K |
| NetLongTermDebtIssuance | -297.02K | 0.00 | 0.00 | -177.74K |
| LongTermDebtPayments | -327.02K | 0.00 | 0.00 | -414.24K |
| LongTermDebtIssuance | 30.00K | 0.00 | 0.00 | 236.50K |
| InvestingCashFlow | 0.00 | -360.19K | -1.72M | -805.97K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -360.19K | -1.72M | -805.97K |
| NetInvestmentPurchaseAndSale | 0.00 | -107.55K | ||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | -107.55K | ||
| NetBusinessPurchaseAndSale | 0.00 | -338.99K | -1.60M | -680.92K |
| PurchaseOfBusiness | 0.00 | -338.99K | -1.60M | -680.92K |
| NetPPEPurchaseAndSale | 0.00 | -21.20K | -119.69K | -17.50K |
| PurchaseOfPPE | 0.00 | -21.20K | -119.69K | -17.50K |
| OperatingCashFlow | -1.81M | -4.19M | -7.40M | -7.60M |
| CashFlowFromContinuingOperatingActivities | -1.81M | -4.19M | -7.40M | -7.60M |
| ChangeInWorkingCapital | -408.42K | 490.77K | 635.57K | -1.61M |
| ChangeInOtherWorkingCapital | 1.61K | 82.22K | -2.60K | -1.08K |
| ChangeInOtherCurrentLiabilities | -168.90K | -351.86K | -2.60K | |
| ChangeInPayablesAndAccruedExpense | 39.87K | 751.71K | 1.85M | -513.55K |
| ChangeInAccruedExpense | 152.82K | 638.76K | 1.61M | -173.15K |
| ChangeInInterestPayable | -2.60K | 0.00 | ||
| ChangeInPayable | -112.95K | 112.95K | 242.47K | -340.40K |
| ChangeInAccountPayable | 0.00 | -23.04K | ||
| ChangeInTaxPayable | -112.95K | 112.95K | 0.00 | |
| ChangeInIncomeTaxPayable | -112.95K | 112.95K | 0.00 | |
| ChangeInPrepaidAssets | 12.95K | 101.93K | 238.09K | -357.28K |
| ChangeInInventory | 0.00 | -25.83K | ||
| ChangeInReceivables | -293.96K | -93.22K | -1.45M | -716.02K |
| ChangesInAccountReceivables | 0.00 | 228.56K | -614.17K | -120.98K |
| OtherNonCashItems | 532.77K | 1.24M | 32.35K | -360.90K |
| StockBasedCompensation | 2.77M | 185.93K | 7.04M | 5.31M |
| ProvisionandWriteOffofAssets | 11.99K | 1.46M | 210.56K | 0.00 |
| AssetImpairmentCharge | 0.00 | 110.12K | 0.00 | |
| DeferredTax | 0.00 | 115.67K | 864.80K | 824.20K |
| DeferredIncomeTax | 0.00 | 115.67K | 864.80K | 824.20K |
| DepreciationAmortizationDepletion | 200.92K | 380.39K | 23.80K | 11.99K |
| DepreciationAndAmortization | 200.92K | 380.39K | 23.80K | 11.99K |
| Depreciation | 200.92K | 380.39K | 23.80K | 11.99K |
| OperatingGainsLosses | 339.17K | 221.89K | 269.84K | |
| GainLossOnInvestmentSecurities | 339.17K | 221.89K | 269.84K | |
| NetIncomeFromContinuingOperations | -5.26M | -8.28M | -16.31M | -12.04M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABVC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|